drugset / Trial / NCT04542837
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.
Timeline
- Start
- 2020-09-11
- Primary completion
- 2022-02-23
- Completion
- 2024-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |